US FDA

21 CFR 211.84 - Testing and Approval or Rejection of Components

Plain-language explanation, inspection context and common violation patterns.

What it says

Each lot of components, drug product containers and closures must be tested or otherwise verified against appropriate specifications before use, and reliance on a supplier's certificate of analysis in place of full testing is permitted only after the reliability of that supplier's analyses has been established through appropriate validation.

Paraphrased for plain-language clarity. Always verify against the current published regulation text.

What it means in practice

What FDA inspectors look for

Most common violation

Relying on a supplier's certificate of analysis for release testing without documented evidence the supplier's analytical reliability was ever formally validated, or skipping identity testing on incoming active pharmaceutical ingredient lots based on a strong supplier audit history alone.

Related regulations

Want a deeper, interactive breakdown?

GMPify's Regulation Explainer tool gives subscribers an AI-powered analysis of any 21 CFR, EU GMP, USP or ICH reference, with live inspection context.

Try the Regulation Explainer →